Relapsed/Refractory Primary Central Nervous System Lymphoma
3 clinical trials · Condition
◉ Watch Relapsed/Refractory Primary Central Nervous System Lymphoma
| Record | Firm | Date |
|---|---|---|
| Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma (NCT07555561) | Beijing Boren Hospital | 2026-09-01 |
| IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (NCT07104032) | Ono Pharmaceutical Co., Ltd. | 2026-06-12 |
| A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT06556199) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-08-31 |
Track Relapsed/Refractory Primary Central Nervous System Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.